AimedBio授权ADC在一期试验中观察到肿瘤缩小

AimedBio's global licensing partner has confirmed tumor reduction in a Phase 1 trial of an antibody-drug conjugate (ADC)-based anticancer drug candidate.
AimedBio said on the 21st that its FGFR3-targeting ADC "AMB302 (BHV-1530)," licensed out to U.S.-based Biohaven, produced objective responses with reduced tumor size in patients with multiple cancer types during the Phase 1 trial.
Notably, BHV-1530 demonstrated clinical efficacy not only in FGFR3-mutated tumors but also in tumors with FGFR3 protein overexpression. Unlike existing FGFR small-molecule inhibitors, which mainly target patients with mutations, this showed the potential for use in a broader patient group, the company explained.
BHV-1530 is currently undergoing a Phase 1 dose-escalation study. The dose-limiting toxicity (DLT) level has not yet been reached, and the major class toxicities known from existing FGFR inhibitors have not been observed to date. Biohaven plans to release updated clinical data at the European Society for Medical Oncology (ESMO) 2026 in October.
Biohaven also plans to launch a combination trial of BHV-1530 with an immuno-oncology agent in the second half of this year to verify the potential for expanded efficacy. Accordingly, it has signed a supply agreement with Regeneron for clinical-grade supplies of the PD-1 immuno-oncology drug "Libtayo."
"Eli Lilly's FGFR3 ADC previously failed to confirm objective responses in its Phase 1 trial," an AimedBio official said. "By contrast, BHV-1530 confirmed objective responses in multiple patients, including those with not only FGFR3 mutations but also overexpressed tumors, marking the first time the clinical potential of an FGFR3 ADC has been made visible."